Skip to main content
Volume 7, No 3 - Summer 2007

Volume 7, No 3 - Summer 2007

Table of Contents

New Guidelines for Helicobacter pylori: Applying Them to Your Practice Management Update
The most recent European Helicobacter Study Group consensus recommendations are a state-of-the-art evaluation of the literature on Helicobacter pylori. The traditional indications for H. pylori eradication remain the major indications for eradication therapy in 2007. A role for H. pylori infection has been demonstrated in disease states that were not traditionally thought to be related to H. pylori infection, namely iron deficiency anemia unexplained by other causes, and idiopathic thrombocytopenic purpura. Office-based H. pylori tests are no longer recommended by the consensus group because of their poor sensitivity and specificity in clinical practice. The treatment of H. pylori infection has not changed significantly in the last decade, though promising alternatives are being studied. At present the treatment regimen recommended for world-wide use is triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Culture and antimicrobial sensitivity testing are recommended in areas where resistance rates to clarithromycin are high. [Rev Gastroenterol Disord. 2007;7(3):111-114]
Fresh Perspectives in Chronic Constipation and Other Functional Bowel Disorders Treatment Update
Functional bowel disorders (FBDs) such as chronic constipation and irritable bowel syndrome-constipation predominant (IBS-C) often share symptoms, but thanks to advances such as the Rome III criteria, diagnosis of these conditions in the absence of alarm features can be relatively straightforward. Empiric treatment is recommended for most patients, with diagnostic testing reserved for those with alarm symptoms. Most current therapies for constipation are indicated for patients with occasional symptoms, with only lubiprostone and tegaserod (restricted) indicated for chronic constipation. Therapies for IBS-C also are limited. However, ongoing research provides promise for improved outcomes in patients with FBDs. [Rev Gastroenterol Disord. 2007;7(3):116-133]
Best of DDW 2007 Meeting Review
Highlights from the 2007 Digestive Disease Week May 19-24, 2007, Washington, DC [Rev Gastroenterol Disord. 2007;7(3):134-166]
Latest Breakthroughs in Chronic Hepatitis B and C Meeting Review
Highlights from the 42nd Annual Meeting of the European Association for the Study of the Liver, April 11-15, 2007, Barcelona, Spain; and the 2007 Digestive Disease Week, May 19-24, 2007, Washington, DC [Rev Gastroenterol Disord. 2007;7(3):167-175]